Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of albumin-bound sirolimus injection in progressive or symptomatic epithelioid hemangioendothelioma
CTR20262541Phase 2Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sirolimus in epithelioid hemangioendothelioma (EHE), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Jul 2026; status: active.
02
Drugs
sirolimus
03
Conditions
epithelioid hemangioendothelioma (EHE)
Beyond the preview
Go deeper on CTR20262541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262541.